Clinical Trial Update: A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia [Phase 1]

View source ↗

Summary

A Phase 1 safety and pharmacokinetic study evaluated paliperidone palmitate in patients with schizophrenia, describing its PK profile and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED